Phase 3 LEVEL Study Hits Enrollment Target, New Trial Initiated as Tenax Reports Wider Q4 Loss
TENX has more than doubled off its 52-week low of $4.63 on elevated volume (2.1× avg).
Summary
Tenax Therapeutics reported a widened Q4 net loss of $15.5 million, primarily driven by increased research and development expenses. These higher R&D costs are attributed to significant progress in its clinical pipeline, including achieving the randomization target for its Phase 3 LEVEL study, with topline data now expected in Q3 2026. The company also initiated the global Phase 3 LEVEL-2 trial. For a clinical-stage biotech, advancing two Phase 3 trials and hitting a key enrollment milestone is a material operational positive, indicating crucial pipeline progression. While the widened loss is a financial negative, it is a direct investment in these critical value-driving assets. Investors will now focus on the upcoming topline data from the LEVEL study and continued enrollment for LEVEL-2, with the company expecting cash reserves to fund operations through 2027.
At the time of this announcement, TENX was trading at $10.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $68.8M. The 52-week trading range was $4.63 to $18.38. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.